Ensysce Biosciences Secures Taiwan Patent for MPAR® Overdose Protection, Extending IP Through 2042
Summary
Ensysce Biosciences announced the issuance of a patent by the Taiwan Intellectual Property Office for its MPAR® (Multi-Pill Abuse Resistance) technology. This patent expands the company's intellectual property estate, providing protection through 2042 in Taiwan and building on a U.S. patent issued in April. For a clinical-stage pharmaceutical company, securing and expanding patent protection for a core, FDA Breakthrough Therapy-designated technology like MPAR® is a material positive development. It strengthens the company's competitive moat and long-term value proposition, especially given its small market capitalization. Traders will monitor further international IP developments and progress in clinical trials for the MPAR® and TAAP™ platforms.
At the time of this announcement, ENSC was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.30 to $2.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Access Newswire.